MephamT.B., CombesR.D., BallsM., BarbieriO., BlokhuisH.J., CostaP., CrillyR.E., de Cock BuningT., DelpireV.C., O'HareM.J., HoudebineL-M., van KreijlC.F., van der MeerM., ReinhardtC.A., WolfE., & van ZellerA-M. (1998). The use of transgenic animals in the European Union. The report and recommendations of ECVAM workshop 28. ATLA26, 21–43.
2.
MortonD.B., & GriffithsP.H. (1995). Guidelines on the recognition of pain, distress and discomfort in experimental animals. Veterinary Record116, 431–436.
3.
Anon. (1989). Guidelines for the Recognition and Assessment of Pain in Animals.UFAW: St Albans, UK.
4.
Anon. (1994). Pain and distress in laboratory rodents and lagomorphs. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Pain and Distress. Laboratory Animals28, 97–112.
5.
TennantR.W., SpaldingJ., & FrenchJ.E. (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutation Research365, 119–127.
6.
Van DeunK., van CauterenH., VandenbergheJ., CanningM., VanparysP., & CoussementW. (1997). Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals. Adverse Drug Reactions and Toxicological Reviews16, 215–233.
7.
Anon. (1997). Testing for Carcinogenicity of Pharmaceuticals. ICH Harmonised Tripartite Agreement, 7 pp. Geneva, Switzerland: ICH.
8.
CombesR.D., & EarleL.K. (1999). BTS Special Symposium. In vitro toxicology — priorities for the year 2000. University of Surrey, 23 April 1998. Report of a symposium to discuss the BTS working party report on in vitro toxicology. Human and Experimental Toxicology18, 126–136.